RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsThe future of ADCs in breast cancer, as in other solid tumors, is to have a landscape of multiple ADCs targeting different tumor antigens with different payloads, in combination with novel sequences and combinations (such as OVs like pelareorep + immune checkpoint inhibiotors) ) some even targeting antigens that are expressed by the tumor microenvironments and the tumor cells (which a combination therapy of OV + immune checkpoint inhibitors can effectively target).